CARTHERA

Their core work

CARTHERA is a Paris-based medical device SME that has developed an implantable ultrasound device designed to temporarily open the blood-brain barrier (BBB), enabling chemotherapy drugs to reach brain tumors — particularly glioblastoma — that would otherwise be unreachable. Their core technology, LIPU (Low-Intensity Pulsed Ultrasound), is an implantable chip that emits acoustic pulses to transiently disrupt the BBB and enhance drug penetration into tumor tissue. As a commercial-stage company, they sit at the intersection of neurosurgery, oncology, and medical devices, working with clinical partners to validate and commercialize their approach. Their work directly addresses one of the hardest problems in neuro-oncology: getting drugs past the brain's natural chemical defense.

What they specialise in

How they've shifted over time

CARTHERA's H2020 trajectory moves from being an industry partner embedded in an academic research training network (GLIOTRAIN, 2017) to leading their own commercial-phase SME Instrument project (DOMEUS, 2020) — a clear shift from R&D validation to product commercialization. The absence of specific keywords in GLIOTRAIN versus the dense, application-focused keyword set in DOMEUS (ultrasound, drug delivery, medical device, LIPU) reflects a company that moved from contributing know-how to a scientific consortium to actively driving a funded clinical-commercial program. This arc — academic partner to project coordinator with EUR 2M+ in Phase 2 SME funding — suggests CARTHERA reached a commercialization inflection point around 2019-2020.

CARTHERA is moving toward clinical and commercial validation of their implantable BBB-opening device, making them a likely partner for clinical trial consortia, oncology-focused drug developers, and neurosurgery centers seeking to combine their technology with novel therapeutics.

How they like to work

CARTHERA demonstrates both followership and leadership in their short H2020 record: they entered the ecosystem as an industry partner in a large academic training network, then matured into coordinating their own SME Instrument project. With 22 unique partners across 8 countries from just 2 projects, their network is broad relative to their project count, suggesting they build wide consortia rather than relying on a fixed circle of repeat collaborators. They appear to function as a technology anchor — bringing a proprietary device that other partners (clinicians, pharmacologists, academic labs) build around.

Despite only two projects, CARTHERA has connected with 22 distinct partners across 8 countries, indicating a deliberate strategy to build multi-stakeholder consortia around their technology. Their network spans academic oncology centers, clinical partners, and research institutions across Europe, consistent with the clinical validation needs of a medical device company.

What sets them apart

CARTHERA occupies an extremely narrow and defensible niche: they are among the very few companies globally with a clinically-tested, implantable ultrasound device specifically designed to open the blood-brain barrier for drug delivery to brain tumors. This is not a research concept — their EUR 2M+ SME Phase 2 funding confirms they were in active commercial development. For any consortium working on brain cancer, CNS drug delivery, or neuro-oncology therapeutics, CARTHERA brings something no academic lab can replicate: a proprietary device platform with clinical-stage development history and the commercial drive of an SME.

Highlights from their portfolio

• DOMEUS
  CARTHERA's flagship project as coordinator — a Phase 2 SME Instrument grant of EUR 2,064,325 specifically to commercialize their LIPU ultrasound device for defeating the blood-brain barrier in glioblastoma treatment.
• GLIOTRAIN
  A Marie Skłodowska-Curie training network on glioblastoma where CARTHERA participated as an industry partner, demonstrating early integration into Europe's top academic neuro-oncology research community.